Sunesis Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Sunesis Pharmaceuticals's estimated annual revenue is currently $7.5M per year.
- Sunesis Pharmaceuticals's estimated revenue per employee is $174,419
- Sunesis Pharmaceuticals's total funding is $184.3M.
Employee Data
- Sunesis Pharmaceuticals has 43 Employees.
- Sunesis Pharmaceuticals grew their employee count by 2% last year.
Sunesis Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Technical Operations | Reveal Email/Phone |
2 | Chief Scientific Officer, EVP R&D | Reveal Email/Phone |
Sunesis Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Sunesis Pharmaceuticals?
We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs. We have built our product candidate portfolio through internal discovery and the in-licensing of novel cancer therapeutics. We are advancing our product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. We believe the quality and breadth of our product candidate pipeline, platform technology, strategic collaborations and scientific team will enable us to become a fully integrated biopharmaceutical company with a diversified portfolio of novel therapeutics for major diseases.
keywords:N/A
$184.3M
Total Funding
43
Number of Employees
$7.5M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sunesis Pharmaceuticals News
Clavis Pharma; Eisai; Genzyme Corporation; Sunesis Pharmaceuticals. Topographically, the accompanying districts, just as the public/nearby...
... Karo Pharma AB, GlaxoSmithKline plc, Novartis AG, Sunesis Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Par Pharmaceutical...
Viracta Therapeutics Inc., formerly known as Sunesis Pharmaceuticals Inc., is based in SAN DIEGO. Get Viracta Therapeutics alerts:.
SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of its non-voting Series F Convertible Preferred Stock (“Seri ...
Total Gross Proceeds of $138.3 Million Assuming the Potential Exercise of All Warrants SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock tog ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35M | 43 | 8% | N/A |
#2 | $3.4M | 43 | -12% | N/A |
#3 | $10M | 43 | 5% | N/A |
#4 | $5M | 43 | 5% | N/A |
#5 | $892.7M | 44 | 0% | $54.8M |